|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment显示文摘AIM:To compare the reliability of gastritis staging sys-tems in ranking gastritis-associated cancer risk in a large series of consecutive patients.METHODS:Gastric mucosal atrophy is the precancer-ous condition in which intestinal-type gastric cancer(GC)most frequently develops.The operative link for gas-tritis assessment(OLGA)staging system ranks the GC risk according to both the topography and the severity of gastric atrophy(as assessed histologically on the ba-sis of the Sydney protocol for gastric mucosal biopsy).Both cross-sectional and long-term follow-up trials have consistently associated OLGA stages Ⅲ-Ⅳ with a higher risk of GC.A recently-proposed modification of the OLGA staging system(OLGIM)basically incorporates the OLGA frame,but replaces the atrophy score with an assessment of intestinal metaplasia(IM)alone.A series of 4552 consecutive biopsy sets(2007-2009)was re-trieved and reassessed according to both the OLGA and the OLGIM staging systems.A set of at least 5 biopsy samples was available for all the cases considered.RESULTS:In 4460 of 4552 cases(98.0%),both the high-risk stages(Ⅲ + Ⅳ)and the low-risk stages(0 +Ⅰ + Ⅱ)were assessed applying the OLGA and OL-GIM criteria.Among the 243 OLGA high-risk stages,14(5.8%)were down-staged to a low risk using OLGIM.The 67(1.5%)incidentally-found neoplastic lesions(intraepithelial or invasive)were consistently associated with high-risk stages,as assessed by both OLGA and OLGIM(P < 0.001 for both).Two of 34 intestinal-type GCs coexisting with a high-risk OLGA stage(stage Ⅲ)were associated with a low-risk OLGIM stage(stage Ⅱ).CONCLUSION:Gastritis staging systems(both OLGA and OLGIM)convey prognostically important informa-tion on the gastritis-associated cancer risk.Because of its clinical impact,the stage of gastritis should be included as a conclusive message in the gastritis histol-ogy report.Since it focuses on IM alone,OLGIM staging is less sensitive than OLGA staging in the identif ication of patients at high risk of gastric cancer. | Massimo Rugge Matteo Fassan Marco Pizzi Fabio Farinati Giacomo Carlo Sturniolo Mario Plebani David Y Graham | 2011 | World Journal of Gastroenterology2011，17，41： | 19 |
| 2 | Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives显示文摘Gastric cancer(GC)represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year.In the last decade,the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced GC and granted better survival expectations to the patients.At the same time,global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease,resulting in the identification of new specific and sensitive predictive and prognostic biomarkers and in innovative molecular classifications based on gene expression profiling.Nonetheless,several randomized studies aimed at exploring new innovative agents,such as immune checkpoint inhibitors,failed to demonstrate clinically meaningful survival advantages.Therefore,it is essential to further improve the molecular characterization of GC subgroups in order to provide researchers and medical oncologists with new tools for patients’selection and stratification in future clinical development programs and subsequent trials.The aim of the present manuscript is to provide a global overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC. | Antonio Pellino Erika Riello Floriana Nappo Stefano Brignola Sabina Murgioni Selma Ahcene Djaballah Sara Lonardi Vittorina Zagonel Massimo Rugge Fotios Loupakis Matteo Fassan | 2019 | World Journal of Gastroenterology2019，25，38： | 9 |
| 3 | Autoimmune gastritis:Pathologist's viewpoint显示文摘Western countries are seeing a constant decline in the incidence of Helicobacter pylori-associated gastritis, coupled with a rising epidemiological and clinical impact of autoimmune gastritis. This latter gastropathy is due to autoimmune aggression targeting parietal cells through a complex interaction of auto-antibodies against the parietal cell proton pump and intrinsic factor, and sensitized T cells. Given the specific target of this aggression, autoimmune gastritis is typically restricted to the gastric corpus-fundus mucosa. In advanced cases, the oxyntic epithelia are replaced by atrophic(and metaplastic) mucosa, creating the phenotypic background in which both gastric neuroendocrine tumors and(intestinal-type) adenocarcinomas may develop. Despite improvements in our understanding of the phenotypic changes or cascades occurring in this autoimmune setting, no reliable biomarkers are available for identifying patients at higher risk of developing a gastric neoplasm. The standardization of autoimmune gastritis histology reports and classifications in diagnostic practice is a prerequisite for implementing definitive secondary prevention strategies based on multidisciplinary diagnostic approaches integratingendoscopy, serology, histology and molecular profiling. | Irene Coati Matteo Fassan Fabio Farinati David Y Graham Robert M Genta Massimo Rugge | 2015 | World Journal of Gastroenterology2015，21，42： | 8 |
| 4 | miRNAs in precancerous lesions of the gastrointestinal tract显示文摘In spite of the well-established understanding of the phenotypic lesions occurring in the shift from native epithelia to invasive (adeno) carcinoma, the molecular typing of the precancerous changes in the gastrointestinal tract remains unreliable. In recent years, no biomarkers have aroused as much interest as the miRNAs,a class of non-coding RNA molecules that function as endogenous silencers of numerous target genes. Aberrant miRNA expression is a hallmark of human disease,including cancer. Unlike most mRNAs, miRNAs are both long-living in vivo and very stable in vitro . Such characteristics allow their testing in paraffin-embedded tissue samples, which is essential in the biological profiling of small (phenotypically characterized) preneoplastic lesions of the gastrointestinal tract (as well as in other fields of human pathology). The upcoming challenge lies in the reliable identification of disease-specific targets of dysregulated miRNAs, to enable miRNA testing in the clinical management of the secondary prevention of gastrointestinal cancer. | Matteo Fassan Carlo M Croce Massimo Rugge | 2011 | World Journal of Gastroenterology2011，17，48： | 7 |
| 5 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice显示文摘HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab. This manuscript focuses on HER2 in gastric carcinogenesis, on optimal evaluation of HER2 and on the possible causes which may contribute to inaccurate HER2 evaluation. Similarly to breast cancer HER2 evaluation, standardization of HER2 testing in gastric cancer is necessary in diagnostic practice. The three principle aspects which require consideration are:(1) the choice of sample with regards to cancer morphology- intestinal vs diffuse areas;(2) the choice of scoring criteria- use of HER2 scoring criteria specific for gastric cancer; and(3) the choice of HER2 evaluation methods- use of an algorithm in which both immunohistochemistry and in situ hybridization play a role. Problematic issues include:(1) pre-analytic variables with particular emphasis on fixation;(2) recommended methodology for HER2 assessment(immunohistochemistry vs in situ hybridization);(3) HER2 heterogeneity both within the primary tumor and between primary tumor and metastases;(4) reliability of biopsies in HER 2 evaluation; and(5) quantity of sample(FFPE blocks from surgical specimens or endoscopic biopsies) necessary for an adequate assessment. | Federica Grillo Matteo Fassan Francesca Sarocchi Roberto Fiocca Luca Mastracci | 2016 | World Journal of Gastroenterology2016，22，26： | 3 |
| 6 | PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis显示文摘 | Kathrin Ludwig Matteo Fassan Claudia Mescoli Marco Pizzi Mariangela Balistreri Laura Albertoni Salvatore Pucciarelli Marco Scarpa Giacomo Carlo Sturniolo Imerio Angriman Massimo Rugge | 2013 | Virchows Archiv2013，，1： | 3 |
| 7 | Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas显示文摘 | Eliana Amato Marco dal Molin Andrea Mafficini Jun Yu Giuseppe Malleo Borislav Rusev Matteo Fassan Davide Antonello Yoshihiko Sadakari Paola Castelli Giuseppe Zamboni Anirban Maitra Roberto Salvia Ralph H Hruban Claudio Bassi Paola Capelli Rita T Lawlor Mi | 2014 | J. Pathol2014，，3： | 2 |
| 8 | HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response显示文摘 | Gaia Codolo Matteo Fassan Fabio Munari Andrea Volpe Piefrancesco Bassi Massimo Rugge Francesco Pagano Mario Milco D’Elios Marina Bernard | 2012 | Cancer Immunology Immunotherapy2012，，1： | 2 |
| 9 | Programmed cell death 4 protein in esophageal cancer显示文摘 | Fassan M Cagol M Pennelli G | 2010 | Oncol Rep2010，24，1： | 1 |
| 10 | The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis显示文摘 | Fassan M Pizzi M Realdon S | 2013 | Human pathology2013，44，9： | 1 |
| 11 | Advanced precancerous lesions within the GI tract: The molecular background显示文摘 | Matteo Fassan Raffaele Baffa András Kiss | 2013 | Best Practice & Research Clinical Gastroenterology2013，，2： | 1 |
| 12 | The Reliability of Endoscopic Biopsies in Assessing Her-2 Status in Gastric and Gastroesophage- al Junction Callcer: A Study Comparing Biopsies with Surgical Sam- ples显示文摘 | Grillo F Fassan M Ceccaroli C | 2013 | Transl Oncol2013，6，1： | 1 |
| 13 | MicroRNA expression profiling of male breast cancer显示文摘 | Fassan M Baffa R Palazzo JP | 2009 | Breast Cancer Res2009，11，4： | 1 |
| 14 | Programmed cell death 4 ( PDCD4 ) expression during muhistep Barrett' s carcinogenesis显示文摘 | Fassan M Pizzi M Battaqlia G | 2011 | J Clin Pathol2011，，3： | 1 |
| 15 | Micro RNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis显示文摘 | Fanni Gelley Gergely Zadori Balazs Nemes Matteo Fassan Gabor Lendvai Eniko Sarvary Attila Doros Zsuzsanna Gerlei Peter Nagy Zsuzsa Schaff Andras Kiss | 2014 | J Gastroenterol Hepatol2014，，1： | 1 |
| 16 | Programmed cell death 4 (PD CD4) expression during multistep Barrett's eareinogenesis显示文摘 | Fassan M Pizzi M Battaqlia G | 2011 | J Clin Pathol2011，64，3： | 1 |
| 17 | Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling 显示文摘 | FASSINA A CAPPELLESSO R FASSAN M | 2011 | Chest2011，140，5： | 1 |
| 18 | Long-Term Follow-up of Barrett’s Epithelium: Medical Versus Antireflux Surgical Therapy显示文摘 | Giovanni Zaninotto Paola Parente Renato Salvador Fabio Farinati Chiara Tieppo Nicola Passuello Lisa Zanatta Matteo Fassan Francesco Cavallin Mario Costantini Claudia Mescoli Giorgio Battaglia Alberto Ruol Ermanno Ancona Massimo Rugge | 2012 | Journal of Gastrointestinal Surgery2012，，： | 1 |
| 19 | HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response显示文摘 | Codolo G Fassan M Munari F | 2012 | Cancer Immunology Immunotherapy:CII2012，61，1： | 1 |
| 20 | PDCD4 nuclear loss inversely correlates with miR-2 l levels in colon carci- nogenesis显示文摘 | Fassan M Pizzi M Giacomelli L | 2011 | Virchows Arch2011，458，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员